Bicycle Therapeutics (BCYC) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Platform overview and technology differentiation

• Bicycle molecules are small, fully synthetic peptides with high selectivity and affinity, offering rapid tissue penetration and renal elimination.

• The platform enables structure-enabled medicinal chemistry for optimization and plug-and-play payload conjugation.

• Manufacturing uses established peptide chemistry, resulting in lower costs compared to biologics.

Strategic focus and pipeline prioritization

• Current focus is on Bicycle toxin conjugates and radionuclide conjugates, with reduced emphasis on early-stage immuno-oncology programs.

• Plans to collaborate on earlier-stage IO assets while advancing the CD137 franchise and targeted agonists.

• External validation from academic groups supports the radiopharma pipeline's potential.

Clinical development and trial updates

• BT8009 (Zeli) shows efficacy comparable to Padcev with a differentiated safety profile, notably lower neuropathy and skin reactions.

• Duravelo-2 trial design aims for both accelerated and confirmatory first-line approval, with interim analyses guiding dose selection.

• Regulatory discussions have set higher benchmarks, requiring statistical superiority over chemotherapy and improved duration of response and safety.

• BT5528 (EphA2-targeting) demonstrates tumor penetration and favorable safety, overcoming limitations seen with prior ADCs.